Publications by authors named "Brent Burger"

Claim this Profile
P
Patient-Reported Outcomes Following UGN-102 Treatment in Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer: An Analysis of 3 Clinical Trials.
Charles C Peyton, Max Kates, Anagha Nadkarni, Rahul Dhanda, Nikky Ugwuoke, Brent Burger

Urol Pract· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer With UGN-102: Outcomes From the 5-Year Long-Term Extension Study of the Single-Arm, Phase 2b Optima II Study.
Neal D Shore, K Kent Chevli, Daniel Saltzstein, Yaron Ehrlich, Jay D Raman, Brent Burger

Clin Genitourin Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of UGN‑102, an investigational mitomycin‑containing reverse thermal gel for the treatment of non-muscle invasive bladder cancer.
Sandip M Prasad, Michael J Louie, Brent Burger, Victoria Tsurutis, Nikky Ugwuoke

Cancer Chemother Pharmacol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Outcomes of Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma With UGN-101, a Mitomycin Reverse Thermal Gel.
Phillip M Pierorazio, Nir Kleinmann, Ahmad Shabsigh, Brian Hu, Jay D Raman, Brent Burger

J Urol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary Chemoablation of Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer With UGN-102: A Single-Arm, Open-Label, Phase 3 Trial (ENVISION).
Sandip M Prasad, Dimitar Shishkov, Nikola Vladimirov Mihaylov, Alexandre Khuskivadze, Pencho Genov, Brent Burger

J Urol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of Low-grade Intermediate-risk Nonmuscle-invasive Bladder Cancer With UGN-102 ± Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS).
Sandip M Prasad, William C Huang, Neal D Shore, Brian Hu, Marc Bjurlin, Brent Burger

J Urol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
Nancy Kemeny, Carlos A Garay, Jayne Gurtler, Howard Hochster, Peter Kennedy, Brent Burger

J Clin Oncol· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.
Mace L Rothenberg, Amit M Oza, Robert H Bigelow, Jordan D Berlin, John L Marshall, Brent G Burger

J Clin Oncol· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis